Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, 53 weeks study on analgesic efficacy and safety of naproxcinod (HCT 3012): 26-week, randomized, parallel-group, double-blind, placebo (13 weeks)- and naproxen (26 weeks)-controlled, multicenter study of naproxcinod (375 mg Bid and 750 mg Bid) with a 26-week naproxen-controlled safety follow-up in subjects with osteoarthritis of the knee, and a 1-week post-treatment safety follow-up

Trial Profile

A phase 3, 53 weeks study on analgesic efficacy and safety of naproxcinod (HCT 3012): 26-week, randomized, parallel-group, double-blind, placebo (13 weeks)- and naproxen (26 weeks)-controlled, multicenter study of naproxcinod (375 mg Bid and 750 mg Bid) with a 26-week naproxen-controlled safety follow-up in subjects with osteoarthritis of the knee, and a 1-week post-treatment safety follow-up

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2011

At a glance

  • Drugs Naproxcinod (Primary) ; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors NicOx
  • Most Recent Events

    • 23 Jul 2010 FDA does not approve NDA according to a media release from NICOX.
    • 03 May 2010 Undisclosed results from a pre-specified pooled analysis of the 301, 302 and 303 naproxcinod studies were presented at ASH 2010, according to a NicOx media release. The abstract has been published in the Journal of Clinical Hypertension 2010, 12 (s1), A5.
    • 01 May 2010 Prespecified pooled pharmacodynamic analysis presented at the 25th Annual Scientific Meeting of the American Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top